非小细胞肺癌同期EBUS-TBNA与液体活检中二代测序的临床效用
该前瞻性观察队列研究纳入199例非小细胞肺癌患者,比较同期EBUS-TBNA与液体活检通过二代测序检测临床相关突变的诊断率差异。EBUS-TBNA对临床相关靶点的检出率高于血液,但部分患者仅在血液中检出突变,提示血液检测具有补充价值。
要点
- EBUS-TBNA对临床相关突变的检出率高于液体活检,差异有统计学意义。
- 部分患者仅在血液中检出突变,液体活检可作为组织检测的补充。
- 需优化二代测序周转时间及样本不足的定义。
核心结论
- EBUS-TBNA比血液更可能检出突变,但部分患者仅在血液中检出突变,提示血液检测具有补充价值。
研究设计与样本
- 前瞻性观察队列研究,纳入199例接受同期活检的非小细胞肺癌患者。
主要发现
- EGFR诊断率在EBUS-TBNA为9.5%,血液为7.0%,诊断率差异2.5%(95% CI: 3.4%, 8.5%,p=0.36)。
- 临床相关靶点检出EBUS-TBNA为79例(39.7%),血液为49例(29.6%),诊断率差异15.1%(95% CI: 5.5%, 24.2%,p=0.001)。
- 以组织结果为金标准,血液检测临床相关突变的敏感性0.53(95% CI: 0.42, 0.64),特异性0.95(95% CI: 0.90, 0.98),阳性预测值0.89(95% CI: 0.77, 0.96),阴性预测值0.74(95% CI: 0.65, 0.81),kappa统计量0.51(95% CI: 0.39, 0.63)。
- 37例(18.6%)仅组织有突变,7例(3.5%)仅血液有突变,42例(21.1%)两种来源均报告突变。
临床怎么用
- EBUS-TBNA应作为突变检测的主要组织来源,液体活检可补充检出组织阴性患者的突变。
- 需关注二代测序周转时间和样本不足对检测的影响。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
RATIONALE: Genetic testing is standard of care in Non-small Cell Lung Cancer(NSCLC). Few studies evaluate concurrent Endobronchial Ultrasound-Transbronchial Needle Aspiration(EBUS-TBNA) and liquid biopsy for Next Generation Sequencing(NGS). OBJECTIVES: Compare diagnostic yield differences for detecting clinically relevant mutations via NGS in concurrent EBUS-TBNA and liquid biopsies. METHODS: Prospective observational cohort study of NSCLC patients undergoing concurrent biopsies. MEASUREMENTS: Yield differences, receiver operating characteristic (ROC) and kappa statistics were calculated for clinically relevant mutations. MAIN RESULTS: Of 199 subjects, diagnostic yield for EGFR was 9.5% in EBUS-TBNA and 7.0% in blood with yield difference 2.5%(95% CI: 3.4%, 8.5%, p = 0.36). For clinically relevant targets, there were 79(39.7%) from EBUS-TBNA and 49(29.6%) from blood with yield difference 15.1%(95% CI: 5.5%, 24.2%, p = 0.001). ROC statistics for detection of clinically relevant mutations (where tissue results were the gold standard) included: sensitivity 0.53 (95% CI: 0.42, 0.64), specificity: 0.95(95% CI: 0.90,0.98), positive predictive value: 0.89 (95% CI: 0.77, 0.96), negative predictive value: 0.74 (95% CI: 0.65, 0.81), and kappa statistic: 0.51 (95% CI: 0.39, 0.63). There were 37 (18.6%) participants with mutations in tissue only and 7(3.5%) with mutations in blood only, while 42(21.1%) had mutations reported from both sources. CONCLUSIONS: EBUS-TBNA was more likely to detect mutations than blood. However, some patients had mutations in blood only, suggesting blood testing is complementary. Strategies are needed to improve NGS turnaround time(TAT) and QNS definition.
引用
- Pastis NJ, Fox AH, Ferguson T, et al. Clinical Utility of Next Generation Sequencing in Concurrent EBUS-TBNA and Liquid Biopsies in NSCLC. Am J Respir Crit Care Med. 2026. PMID: 42475517. doi:10.1093/ajrccm/aamag372
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。